Rankings
▼
Calendar
URGN FY 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$48M
+307.2% YoY
Gross Profit
$43M
89.3% margin
Operating Income
-$92M
-192.1% margin
Net Income
-$111M
-230.7% margin
EPS (Diluted)
$-4.96
Cash Flow
Operating Cash Flow
-$85M
Free Cash Flow
-$86M
Stock-Based Comp.
$23M
Balance Sheet
Total Assets
$120M
Total Liabilities
$111M
Stockholders' Equity
$8M
Cash & Equivalents
$44M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$48M
$12M
+307.2%
Gross Profit
$43M
$11M
+297.5%
Operating Income
-$92M
-$127M
+27.2%
Net Income
-$111M
-$128M
+13.7%
← Q4 2020
All Quarters
Q1 2021 →